Placement of Covered Stents for Carotid Blowout in Patients with Head and Neck Cancer: Follow-up Results after Rescue Treatments


AJNR Am J Neuroradiol 2007, 28 (8) 1594-1598
doi: https://doi.org/10.3174/ajnr.A0589
http://www.ajnr.org/content/28/8/1594
Placement of Covered Stents for Carotid Blowout in Patients with Head and Neck Cancer: Follow-up Results after Rescue Treatments

BACKGROUND AND PURPOSE: Placement of a covered stent to control carotid blowout (CB) in malignant tumors of the head and neck has been reported to be an effective treatment. However, it is not uncommon to encounter recurrent hemorrhage. The purpose of this study was to evaluate the follow-up results of patients treated with covered stents.

MATERIALS AND METHODS: We retrospectively reviewed the results of 7 consecutive patients who underwent placement of a covered stent to control CB. Most of them had poor wound healing because of previous irradiation, surgery, or both. The initial procedures were successful in all patients. Their clinical course was reviewed for rebleeding, additional endovascular treatments in recurrent cases, and outcomes.

RESULTS: Recurrence developed in 6 of 7 patients. The interval between the first procedure and the hemorrhagic event was from 3 to 44 days. In 6 patients who had a recurrent CB, 4 had rebleeding from the previous site of the stent, whereas 2 other patients experienced recurrent bleeding in a different area from the site of the stent. Additional endovascular treatments were carried out in all affected patients by another insertion of a covered stent (n = 3), coil embolization (n = 2), or insertion of a covered stent followed by permanent arterial occlusion (n = 1).

CONCLUSION: Placement of a covered stent in patients with head and neck cancer who sustain CB showed frequent rebleeding despite favorable initial rescue results. Recurrent CB at the previous stent site developed frequently in patients with uncontrolled wound infection. Concomitant or short-interval arterial trapping should be considered selectively in those conditions.
<table>
<thead>
<tr>
<th>Age/Sex</th>
<th>Clinical History</th>
<th>Treatment</th>
<th>Fistular Formation</th>
<th>Flap Surgery</th>
<th>Infection</th>
<th>Initial Site</th>
<th>Rebleeding</th>
<th>Recurrence Site</th>
<th>Interval between Two Events</th>
<th>Clinical Course</th>
</tr>
</thead>
<tbody>
<tr>
<td>62/M</td>
<td>Esophageal ca, Lt supraclavicularly lymphadenopathy</td>
<td>RTx, I &amp; O(2)</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Lt mid CCA</td>
<td>Yes</td>
<td>Proximal end of the stent margin</td>
<td>10 days</td>
<td>Recurrent hemorrhage on 2 months F/U</td>
</tr>
<tr>
<td>50/M</td>
<td>Nasopharyngeal ca</td>
<td>RTx(2), skull base op. w ND (Rt), PMMC flap, free flap, I &amp; O</td>
<td>Yes</td>
<td>Unfavorable result</td>
<td>Yes</td>
<td>Rt carotid bulb</td>
<td>Yes</td>
<td>Proximal end of the stent margin</td>
<td>44 days</td>
<td>Permanent carotid artery occlusion for recurrent bloody sputum after the second stent placement, death after 8 months</td>
</tr>
<tr>
<td>67/M</td>
<td>Laryngeal ca</td>
<td>RTx, TL w both ND several flap surgery</td>
<td>Yes</td>
<td>Favorable result</td>
<td>Yes, streptococcus</td>
<td>Lt mid CCA</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
<td>Death 1 month later, no recurrent hemorrhage</td>
</tr>
<tr>
<td>64/M</td>
<td>Laryngeal ca</td>
<td>RTx(2) TL w both ND</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Rt distal CCA</td>
<td>Yes</td>
<td>Rt ECA branch</td>
<td>3 days</td>
<td>Discharge in stable condition 2 weeks later and lost F/U</td>
</tr>
<tr>
<td>69/M</td>
<td>Laryngeal ca</td>
<td>RTx, TL w both ND, PMMC</td>
<td>Yes</td>
<td>Unfavorable result</td>
<td>Yes</td>
<td>Rt distal CCA</td>
<td>Yes</td>
<td>Distal end of the stent margin</td>
<td>23 days</td>
<td>Discharge for palliative care and lost F/U</td>
</tr>
<tr>
<td>55/F</td>
<td>Hypopharyngeal ca</td>
<td>RTx, TLPE w ND(Rt)</td>
<td>Yes</td>
<td>Unfavorable result</td>
<td>Yes, Klebsiella</td>
<td>Lt distal CCA</td>
<td>Yes</td>
<td>Distal end of the stent margin</td>
<td>11 days</td>
<td>Discharge for palliative care and lost F/U</td>
</tr>
<tr>
<td>80/M</td>
<td>Hypopharyngeal ca</td>
<td>RTx(2)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Rt mid CCA</td>
<td>Yes</td>
<td>Lt mid CCA</td>
<td>40 days</td>
<td>Death from sepsis 10 days after the second stent placement</td>
</tr>
</tbody>
</table>

Note:—Ca indicates cancer; CCA, common carotid artery; ECA, external carotid artery; F/U, follow-up; I&D, incision and drainage; TLPE, total laryngopharyngoesophagectomy; Lt, left; mid, middle; N/A, not applicable; ND, neck dissection; op, operation; PMMC, pectoralis major myocutaneous; Rt, right; RTx, radiotherapy; TL, total laryngectomy.

The covered stent we used was a self-expandable nitinol stent covered with PTFE (polytetrafluoroethylene) (NITI-S Stent; Taewoong Medical, Seoul, South Korea). In our initial experience, we tried to occlude a leaking pseudoaneurysm by placing several coils and a bare stent combined with a covered stent. Unfortunately, however, this procedure did not offer enough hemostatic effect. We performed additional placement of a covered stent over the bare metallic stent to control the hemorrhage effectively. After we obtained hemostasis, we administered oral antiplatelet medication with 100 mg of aspirin and 75 mg of clopidogrel (Plavix) daily after loading dose to minimize the risk of embolic ischemia and in-stent thrombosis. When secure hemostasis was doubtful on follow-up clinical inspection, or if oozing developed at the wound site, we stopped any antiplatelet medication to prevent possible rebleeding.

**Analysis**

We analyzed the initial clinical and angiographic results after placement of the covered stent. The recurrence rate of hemorrhage, the time interval between initial treatment and recurrent hemorrhage, the focus of recurrence, the condition of the local wound including presence of infection, additional methods of endovascular treatment, and clinical follow-up were analyzing points.

**Results**

The initial clinical and angiographic results of the covered stent placement were successful in the 5 patients who presented with active bleeding (Fig 1) as well as in the other 2 patients with anticipated bleeding (Fig 2).
On angiography, initial lesions were seen in the common carotid artery in all patients except for 1, who experienced leakage at the carotid bulb just above the carotid bifurcation. Placement of a covered stent (diameter, 8–10 mm; length, 40–70 mm) was enough to achieve immediate hemostasis.

Devastating recurrent bleeding was noted in 6 (85%) of 7 patients. The interval between the initial endovascular procedure and the recurrent episode of bleeding was from 3 to 44 days (median, 17 days). Subsequent angiography was immediately performed. Although manifestation of the bleeding episodes was similar to that of the initial events, the lesion sites of recurrent hemorrhages were different in all 6 patients. In 6 patients who sustained recurrent CB, 4 had rebleeding from the site of the previous stent insertion, whereas 2 other patients experienced recurrent bleeding from a completely different site not related to the location of the stent. In the strict sense, the rate of recurrent CB related to failure of stent durability was 57% (4/7). The foci of recurrent bleeding were at the cranial (n = 2) or caudal end (n = 2) of the previously inserted stent margin, a branch of the ipsilateral external carotid artery apart from the stent margin (n = 1), and contralateral common carotid artery (n = 1). We put another covered stent in 4 of these 6 patients. In the other 2 patients, we embolized the bleeding foci by using several metallic coils. An ipsilateral carotid trapping procedure was performed in 1 patient, who showed continuous oozing even after placement of the secondary stent. This patient had 3 endovascular treatments and died 8 months later without any further recurrence of hemorrhage. The successive hemostatic procedures were durable until death from septic cause in 1 patient, or discharge for palliative supportive care in the other 5 patients.

Discussion

CB is one of the most devastating events that both long-standing patients with head and neck cancer and their physicians hope not to face. In several recent studies, endovascular treatment with a covered stent for CB has been reported as a quick and effective method of lower morbidity compared with an operation for treatment of a postsurgical fistula.6-14 Moreover, in emergent and effective method of lower morbidity compared with an operation for treatment of a postsurgical fistula.6-14 However, we encountered a relatively high proportion of patients (6/7) who sustained recurrent active bleeding shortly after the successful first treatment. In fact, recurrence directly related to the site of the stent developed in 4 (57%) of 7 patients. However this ratio also was higher than that in previous reports.11,14,15 All of our patients had undergone radiation therapy with a dose of at least 60 Gy, and 3 patients with recurrent cancer had received a further booster dose of radiation. Irradiation can be attributed as a cause of clinically serious injury of the large arteries, including occlusive disease. In addition, injury of the vasa vasorum after radiation therapy may account for an increased incidence of CB.2,3,16-18

Two patients in our study underwent placement of a covered stent as a prophylactic measure. Nevertheless, both patients experienced massive oral or wound bleeding 1 month after the procedure, thereby requiring the second interventional treatment. Contrary to the case presented by Warren et al,13 in which prophylactic placement of a covered stent in the common carotid artery encaused by a tumor showed good follow-up results, 2 of our patients did not enjoy such benefits. It is worthwhile to mention that these 2 patients had poor wound healing caused by wound dehiscence after pectoralis major myocutaneous flap surgery for treatment of a postsurgical fistula.

In our experience, infection was an important predisposing factor of arterial rupture. In the neck, infection may be manifested by disrupted skin flaps or a pharyngocutaneous fistula.12,17 The myocutaneous flaps are the optimum solution with their independent vascular pedicles. They provide the best environment for wound healing: diversion of salivary stream, and well-vascularized soft tissue so as to exclude it from the contaminated field and scaffolding effect of the stents.12,13 However, failure of the graft might be followed by infection of the local wound. The carotid artery underneath the graft may lose its external supporting soft tissue because of inevitable wound dehiscence or formation of a cutaneous fistula, or both. In 3 of 4 patients who underwent myocutaneous flap surgery, flap necrosis developed. Five of 7 patients sustained various cutaneous fistulas and wound infections with or without previous flap surgery.

There were some possible causes of frequent rebleeding after successful hemostasis. The patients in our study who exhibited recurrent CB were divided into 2 groups according to the site of the rebleeding. The first group, which included patients with a recurrent CB at the site of the stent insertion (4/6), had a fistula with infection followed by flap surgery or incisional drainage. To the contrary, the other group, who had rebleeding from a site different from that of the stent insertion (2/6), did not represent any possible causes that the adjacent rebleeding group had. Therefore, existence of an uncontrolled ongoing infection at the stent site is an important factor to predict a recurrent CB from a previous stent site.

In addition, continuous irritation by stent struts, especially the bare portion at both ends of the covered stent, was another cause of recurrent CB in the group who had rebleeding from the stent site. This factor could explain the cause of frequent rebleeding at both ends of the stent in this group. In addition to the chronic mechanical irritation, the presence of the stent itself could have acted as a foreign body in an unfavorable environment. To solve this problem, a newly designed covered stent with less irritability and more biologic stability should be developed.

The purpose of this report was not to deny the potential role of a covered stent in the management of a CB. Instead, we tried to emphasize that clinicians be aware of the possibility of a recurrent CB, even when the initial rescue procedure is successful. Of course, careful consideration is necessary for all patients who undergo placement of a covered stent for active hemorrhage or as a preventive measure, but more attention is mandatory for patients who have a contaminated area by a fistula, flap failure, or abscessed cavity as a result of tumor necrosis. In these patients under such emergent situations, placement of a covered stent would be the optimum treatment. Once successful control of bleeding is achieved, successive or short-term additional endovascular trapping of the involved artery can be definitely considered. Moreover, endo-
vascular trapping of the involved artery should be the first prophylactic treatment in patients with poor wound healing. Of course, if there is evidence of controlled infection and improvement of the wound, close observation with hold of additional procedures can also be deliberated.

Conclusion
Placement of a covered stent in patients with head and neck cancer who sustain CB showed frequent rebleeding within a short interval despite successful rescue results. Recurrent CB at the previous site of the stent developed frequently in patients with uncontrolled wound infections. After the emergent situation is arrested, if a patient shows tolerant result in temporary occlusion test with a balloon catheter, concomitant or short-interval arterial trapping should be considered selectively in place of covered stent placement.

References